49 related articles for article (PubMed ID: 22473339)
1. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Chou YW; Chaturvedi NK; Ouyang S; Lin FF; Kaushik D; Wang J; Kim I; Lin MF
Cancer Lett; 2011 Dec; 311(2):177-86. PubMed ID: 21862211
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Venkataramani V; Rossner C; Iffland L; Schweyer S; Tamboli IY; Walter J; Wirths O; Bayer TA
J Biol Chem; 2010 Apr; 285(14):10678-89. PubMed ID: 20145244
[TBL] [Abstract][Full Text] [Related]
4. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
Lee JI; Nian H; Cooper AJ; Sinha R; Dai J; Bisson WH; Dashwood RH; Pinto JT
Cancer Prev Res (Phila); 2009 Jul; 2(7):683-93. PubMed ID: 19584079
[TBL] [Abstract][Full Text] [Related]
5. Vikil
Tettey CO; Essuman EK; Aninagyei E; Kwansa-Bentum HT; Agyemang Boakye A; Kortei NK; Boamah D
Integr Cancer Ther; 2024; 23():15347354241253846. PubMed ID: 38721848
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor sodium butyrate regulates the activation of toll-like receptor 4/interferon regulatory factor-3 signaling pathways in prostate cancer cells.
Ozkan AD; Eskiler GG; Kazan N; Turna O
J Cancer Res Ther; 2023 Oct; 19(7):1812-1817. PubMed ID: 38376283
[TBL] [Abstract][Full Text] [Related]
7. Valproic Acid and Breast Cancer: State of the Art in 2021.
Wawruszak A; Halasa M; Okon E; Kukula-Koch W; Stepulak A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298623
[TBL] [Abstract][Full Text] [Related]
8. Sodium valproate, a histone deacetylase inhibitor ameliorates cyclophosphamide-induced genotoxicity and cytotoxicity in the colon of mice.
Khan S; Jena G
J Basic Clin Physiol Pharmacol; 2014 Jan; ():1-11. PubMed ID: 24468617
[TBL] [Abstract][Full Text] [Related]
9. From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer.
Pellegrino M; Ricci E; Ceraldi R; Nigro A; Bonofiglio D; Lanzino M; Morelli C
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139561
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Immune system and Epigenetic Landscape of Urological Tumors.
Lobo J; Jerónimo C; Henrique R
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012885
[TBL] [Abstract][Full Text] [Related]
11. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
[TBL] [Abstract][Full Text] [Related]
12. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.
Forthun RB; Hellesøy M; Sulen A; Kopperud RK; Sjøholt G; Bruserud Ø; McCormack E; Gjertsen BT
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1729-1749. PubMed ID: 31111215
[TBL] [Abstract][Full Text] [Related]
13. Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection.
Danziger O; Shai B; Sabo Y; Bacharach E; Ehrlich M
Oncotarget; 2016 Aug; 7(32):52115-52134. PubMed ID: 27366948
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
[TBL] [Abstract][Full Text] [Related]
15. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
[TBL] [Abstract][Full Text] [Related]
16. RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.
Sutherland M; Gordon A; Shnyder SD; Patterson LH; Sheldrake HM
Cancers (Basel); 2012 Oct; 4(4):1106-45. PubMed ID: 24213501
[TBL] [Abstract][Full Text] [Related]
17. IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.
Erb HH; Langlechner RV; Moser PL; Handle F; Casneuf T; Verstraeten K; Schlick B; Schäfer G; Hall B; Sasser K; Culig Z; Santer FR
Endocr Relat Cancer; 2013 Oct; 20(5):677-89. PubMed ID: 23913484
[TBL] [Abstract][Full Text] [Related]
18. Manipulating the epigenome for the treatment of urological malignancies.
O'Rourke CJ; Knabben V; Bolton E; Moran D; Lynch T; Hollywood D; Perry AS
Pharmacol Ther; 2013 May; 138(2):185-96. PubMed ID: 23353098
[TBL] [Abstract][Full Text] [Related]
19. Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action.
Liu X; Chen L; Sun F; Zhang G
Cytotechnology; 2013 Aug; 65(4):597-608. PubMed ID: 23161221
[TBL] [Abstract][Full Text] [Related]
20. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
